ILC2s are critically involved in allergic responses, but the mechanisms by which they are regulated remain unclear. Li et al. demonstrate that the VHL-HIF axis is essential for ILC2 maturation and function via inhibition of glycolysis and induction of IL-33 receptor expression. These findings have implications for identifying therapeutic targets for allergic diseases.
INTRODUCTION
Innate lymphoid cells (ILCs) are specialized subsets of lymphoid effector cells lacking classical antigen receptors, which are mainly found at barrier surfaces such as the lungs, intestine, and skin, as well as adipose tissue and some mucosal-associated tissues (Klose and Artis, 2016; Spits et al., 2013) . ILCs play important roles in immune defense, inflammation, metabolic homeostasis, and tissue remodeling (Klose and Artis, 2016) . Recent studies have revealed a delicate developmental process for ILC lineage commitment; ILCs originate from common lymphoid progenitors (CLPs) in fetal liver and adult bone marrow (Cherrier et al., 2012; Wong et al., 2012) , which first develop into a-lymphoid precursors (aLPs) upon upregulation of transcription factors ID2, NFIL3, and TOX (Klose et al., 2014; Seehus et al., 2015; Seillet et al., 2014) . aLPs then differentiate into either natural killer cell progenitors (NKPs) upon expression of transcription factors T-bet and EOMES (Daussy et al., 2014) or common helper innate lymphoid progenitors (CHILPs) upon expression of transcription factors TCF1 and GATA3 (Yagi et al., 2014; Yang et al., 2015) . CHILPs are a heterogeneous population that comprises ILC precursors (ILCPs) and lymphoid tissue-inducer (LTi) precursors. Lineagetracing approaches and single-cell transcriptional analysis have defined that the transcription factor PLZF is the decisive regulator for the bifurcation of ILCs and LTi cell lineages (Constantinides et al., 2014; Ishizuka et al., 2016) .
ILCs can be categorized into three subsets on the basis of transcriptional and functional similarities paralleled to T helper (Th) cell subsets (Spits et al., 2013; Zook et al., 2016) . Group 1 ILCs express T-bet and comprise conventional NK cells (cNKs) and interferon-g (IFN-g)-producing ILC1s. Group 2 ILCs express GATA3, RORa, and BCL11b, include several ILC2 populations found in different organs, and produce type 2 cytokines such as interleukin-4 (IL-4), IL-5, IL-9, IL-13, and epidermal growth factor amphiregulin (AREG). Group 3 ILCs express RORgt, which include LTi cells and IL-17-and/or IL-22-producing ILC3s. Among those ILCs, ILC2s can be activated by epitheliumderived cytokines such as IL-33, IL-25, and thymic stromal lymphopoietin (TSLP) and play important roles in anti-helminth infection and inflammatory responses such as allergic diseases (Fan and Rudensky, 2016) .
The von Hippel-Lindau (VHL) disease is an inherited tumorigenic disease, which is generally found in kidney, central nervous system, retina, and pancreas. The VHL protein is the core of an E3 ubiquitin ligase complex, which contains elongin C, elongin B, cullin2, and RING-box protein RBX1 (Gossage et al., 2015) . Hypoxia-inducible factor a-subunit (HIFa) is the most important substrate for VHL E3 complex. Under normoxia conditions, HIFa is hydroxylated by oxygen-dependent prolyl hydroxylases (PHDs), then recognized by VHL, and targeted for poly-ubiquitylation and proteasomal degradation. Under hypoxia conditions, HIFa cannot be hydroxylated; the stabilized HIFa dimerizes with HIF1b and then translocates into the nucleus to initiate the transcriptional regulation of diverse target genes by binding to hypoxia-response elements (HREs) (Schofield and Ratcliffe, 2004) .
Previous studies have shown that HIF transcription factors play important roles in controlling immune cell metabolism, lymphocyte differentiation, and immune responses (Palazon et al., 2014) . Thymocyte-specific deletion of Vhl results in a severe defect in lymphocyte development due to increased cell death mediated by HIF1a (Biju et al., 2004) . HIF1a balances T cell fate determination by promoting Th17 cell generation while impairing differentiation toward T regulatory (Treg) cells (Dang et al., 2011; Shi et al., 2011) . Loss of VHL enhances HIF1a-mediated CD8 + T cell glycolysis and facilitates the effector responses to persistent viral infection (Doedens et al., 2013) . Our recent work has revealed that VHL is a key regulator in maintaining the stability and function of Treg cells via HIF1a . However, whether VHL-HIF pathway is involved in the regulation of ILCs remains unknown. To address this issue, we generated VHL conditional knockout mice to selectively delete VHL expression in ILCPs and demonstrated that VHL plays a pivotal and selective role in the development and function of ILC2s through the HIF1a pathway.
RESULTS

Deletion of Vhl Results in Impaired ILC2 Development
ILCs develop from CLPs through a CHILP stage, which contain a population of ILCPs expressing high levels of PLZF (Constantinides et al., 2014; Ishizuka et al., 2016; Klose et al., 2014) . We first assessed the expression of Vhl and PLZF-encoding Zbtb16 mRNA in hematopoietic progenitors and ILC2s in the bone marrow, as well as mature ILCs in the lungs and intestine by quantitative real-time PCR. Vhl was ubiquitously expressed in these cells, whereas Zbtb16 was distinctively highly expressed in CHILPs ( Figure S1A ). A previous lineage-tracing study has revealed that almost all ILC2s are traced by PLZF expression in the lineage commitment process, whereas ILC1s and ILC3s are labeled to a lesser extent (Constantinides et al., 2014) . To understand whether VHL is involved in the development and function of ILCs, we crossed Vhl fl/fl mice with Zbtb16-cre mice and analyzed the ILC populations in different organs by gating with various cell surface markers including the lineage markers for T, B, NK, and myeloid cells, and commonly used markers including CD90.2, CD127, Sca1, ST2, KLRG1, and ICOS. Transcriptional analysis displayed defective expression of Vhl in bone marrow, lung, and intestinal ILC2s, but not in myeloid cells and ILC1s and ILC3s in Vhl fl/fl Zbtb16-cre mice (Figures S1B-S1D). As most ILC2s ($95%) in bone marrow do not express KLRG1, they are generally recognized as ILC2 precursors (ILC2Ps) or immature ILC2s (Hoyler et al., 2012; Yang et al., 2013) . We found that Vhl fl/fl Zbtb16-cre mice had normal numbers of ILC2s in the bone marrow compared with their wild-type counterparts ( Figure 1A ). However, further detailed flow cytometric analysis revealed different profiles of ILC2-specific surface markers, with lower expression of Sca1, ICOS, and Il17Rb and higher expression of CD44 and CD25 on bone marrow ILC2s from Vhl fl/fl Zbtb16-cre mice than those from wild-type mice ( Figure S1E ). We found a decrease in both frequencies and numbers of ILC2s in multiple peripheral nonlymphoid tissues, including the lungs, small and large intestine, and epididymal white adipose tissue (EWAT) ( Figures  1A and 1B) . However, other ILC populations were not affected, including ILC1s, ILC3s, and LTi cells in the intestine, except for a decrease of ILC1s in the large intestine ( Figures 1C and 1D ). Although NKT cell frequencies and numbers decreased significantly in the liver of Vhl fl/fl Zbtb16-cre mice, they were present at normal frequencies and numbers in the thymus and lungs compared to control mice, together with normal frequencies of lung T and B cells ( Figures S1F-S1H ). Together, these data indicated VHL as a selective and potent regulator for the development of mature ILC2s. (Barlow et al., 2013; Huang et al., 2015) . In naive mice, most ILC2s in the bone marrow lack KLRG1 expression. Intraperitoneal administration of IL-33 promoted the expansion and activation of bone marrow ILC2s in wildtype mice, indicated by increased total cell numbers ( Figures  3A and 3B ) and elevated expression of ST2 and KLRG1, as well as the significantly increased proportion of KLRG1-expressing ILC2s ( Figures 3C and 3D ). However, IL-33 had a negligible effect on bone marrow ILC2s of Vhl fl/fl Zbtb16-cre mice, as the total numbers were not increased ( Figure 3B ) and the ST2 expression level remained significantly lower than the counterpart upon IL-33 treatment ( Figure 3C ). Meanwhile, although IL-33 also drove elevated KLRG1 expression on VHL-deficient bone marrow ILC2s, the enhancement was quite limited Each symbol (B, D) represents an individual mouse. Data are represented as mean ± SD; ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 (two-tailed unpaired t test). Data are pooled from or representative of two to four independent experiments. See also Figure S1 . (legend continued on next page) ( Figure 3D ). In vitro culture of purified bone marrow ILC2s from wild-type mice with IL-7 and IL-33 caused a substantial increase in total cell numbers and production of IL-5 and IL-13, while the same treatment on ILC2s from VHL-deficient mice caused only minor IL-5 and IL-13 secretion and attenuated the increase of ILC2 numbers (Figures S3A and S3B) , indicating a role of VHL in expansion and type 2 cytokine production of ILC2s in response to IL-33 treatment.
ILC2-Mediated Immune Responses in
Similarly, IL-33 administration resulted in an increase in the total numbers and ST2 and KLRG1 expression of lung ILC2s from wild-type mice, whereas the responsiveness of lung ILC2s in Vhl fl/fl Zbtb16-cre mice was decreased ( Figures 3E-3H ).
Additionally, VHL deficiency resulted in reduced accumulation of lung eosinophils and lower concentration of IL-5 in BALF upon IL-33 injection ( Figures 3I and 3J ). Moreover, bone marrow and lung ILC2s from IL-33-treated wild-type mice exhibited high proportions of Ki-67 + cells, whereas proliferation of ILC2s from VHL-deficient mice was significantly lower than their counterpart control (Figures S3C and S3D) . Consistently, IL-33 administration did not elicit ILC2 expansion in EWAT, peritoneal cavity, large intestine, lung-draining lymph nodes, and mesenteric lymph nodes (mLNs) ( Figure S3E ) or eosinophil accumulation in EWAT and peritoneal cavity in Vhl fl/fl Zbtb16-cre mice ( Figure S3F ), with only moderated IL-5 and IL-13 secretion in peritoneal cavity ( Figure S3G ). Thus, loss of VHL resulted in the failure to mount an inflammatory response to IL-33 treatment. 
Il2rg
À/À recipient mice, which were absent of mature T cells, B cells, and ILCs. We analyzed the donor chimerism of ILC2s, ILC3s, and LTi cells from the bone marrow, lungs, and intestine, and normalized to splenic B cells as a control by measuring the ratio of CD45.2 and CD45.1 markers ( Figure 4A ). Fewer ILC2s in the lungs and small and large intestine were detected from CD45.
Zbtb16-cre donor cells compared with the competitor CD45.1 + wild-type donor cells ( Figure 4A ). In contrast, CD45.2 + and CD45.1 + wild-type donor cell-derived chimeras had comparable ILC2 populations among different tissues ( Figure 4A ). However, bone marrow ILC2s, intestinal ILC3s, and LTi cells repopulated to similar extents in the mixed chimeras (Figures 4A and 4B) . Similarly, single bone marrow chimeric mice were generated and challenged with IL-33. Consistently, intraperitoneal IL-33 administration increased total numbers of lung ILC2s derived from CD45.2 + wild-type donor cells but not from CD45.
Zbtb16-cre donor cells ( Figures 4C and 4D) . Therefore, VHL acted in a cell-autonomous manner in regulating the development and function of ILC2s.
VHL Deficiency Inhibits the Differentiation of ILC2s
In Vitro ILC2s can be generated from CLPs or CHILPs in vitro on OP9 stromal cells expressing Delta-like (DL) ligand in the presence of IL-7 and IL-33 (Klose et al., 2014; Wong et al., 2012 to a large extent after 18 days of culture, and most cells also expressed CD44 and CD25, with about 20% of them expressing ST2 ( Figure 5A ). However, CHILPs from Vhl fl/fl Zbtb16-cre mice generated significantly fewer ILC2s compared with those from control mice ( Figures 5A and 5B ). Moreover, we measured the production of type 2 cytokines from the in vitro differentiated cells and found that VHL deficiency dampened the frequencies of IL-5-and/or IL-13-secreting populations ( Figures 5C and  5D ). In addition, as PD-1 hi ILC progenitors are recently identified (Yu et al., 2016) , we used a PD-1 hi progenitor population from control and Vhl fl/fl Zbtb16-cre mice for in vitro ILC2 differentiation and obtained similar results ( Figures S4A and S4B ). These results, together with the bone marrow chimeric studies, clearly indicated that VHL was intrinsically required for the development and function of ILC2s.
VHL-HIF1a Signaling Plays an Essential Role in ILC2s
It is well established that loss of VHL results in the accumulation of HIFa proteins (Maxwell et al., 1999) . We measured the mRNA expression of HIF subunits including HIF1a, HIF2a, and HIF1b and found that HIF1a was the dominant HIF subunit in bone marrow and lung ILC2s ( Figure S5 ). Flow cytometric analysis showed that the expression of HIF1a was indeed increased in ILC2s from Vhl fl/fl Zbtb16-cre mice compared with wild-type ILC2s after IL-33 stimulation (Figures 6A and 6B 
VHL Promotes ILC2 Differentiation by Glycolytic Inhibition
HIF1a preferentially induces the expression of genes that are related to glycolytic pathway, which relies on a chain of catalytic reactions executed by multiple enzymes (Iyer et al., 1998) . To explore whether loss of VHL alters glycolysis in ILC2s, we performed quantitative real-time PCR analysis and found that the expression of several glycolytic enzyme genes was markedly increased in ILC2s from Vhl fl/fl Zbtb16-cre mice compared with wild-type ILC2s ( Figure S6A ). The cellular oxygen-consumption rate (OCR) and extracellular acidification rate (ECAR) were measured as indicators of mitochondrial respiration and aerobic glycolysis, respectively. Consistently, ILC2s from VHL-deficient mice showed less OCR and higher ECAR in comparison to wild-type ILC2s, suggesting that VHL deletion resulted in enhanced glycolytic capacity and attenuated mitochondrial respiration in ILC2s ( Figures  S6B-S6E ).
To further investigate whether aberrant glucose metabolism is responsible for the defects of ILC2s, we tested whether the HIF hydroxylase PHD inhibitor DMOG or TCA cycle inhibitor CPI-613 could influence ILC2 development by using the in vitro co-culture system. We found that DMOG and CPI-613, through enhancing glycolysis or blocking oxidative phosphorylation, could inhibit the differentiation of ILC2s, as annotated by the decreased proportions of CD127 + ST2 + cells from DMOG-or CPI-613-treated CHILPs compared with the untreated control ( Figure S6F) .
To investigate the molecular mechanism of metabolic reprogramming in the development of ILC2s, we tried to manipulate glycolysis at different steps with small molecule agents in vitro. CHILPs from wild-type mice cultured in vitro were treated with 2-deoxyglucose (2-DG), shikonin (SKN), or UK5099, to inhibit hexokinase (HK), pyruvate kinase (PKM2), and mitochondrial pyruvate carrier (MPC), respectively. Treatment with 2-DG or SKN augmented the differentiation of Sca1 + ST2 + ILC2s, whereas UK5099 attenuated ILC2 differentiation ( Figure 7A ). Each symbol in (B) and (D) represents an individual mouse. Data are represented as mean ± SD; ns, not significant; *p < 0.05, ***p < 0.001, and ****p < 0.0001 (two-tailed unpaired t test). Data are pooled from or representative of two to four independent experiments.
We then examined the role of PKM2, which catalyzes the conversion from phosphoenolpyruvate to pyruvate, by shRNAmediated knockdown, and found that decreased PKM2 expression promoted ILC2 differentiation ( Figure 7B ). We next tested whether the glycolytic metabolites pyruvate and lactate are involved in this process in the in vitro co-culture system at different doses. Treatment with pyruvate, but not lactic acid, resulted in decreased differentiation of Sca1 + ST2 + ILC2s (Figure 7C) . These findings elucidated an important role of metabolic reprogramming centered at the PKM2-pyruvate step in ILC2 development.
VHL Deficiency Alters Epigenetic Modification on ST2 Gene
Glucose metabolism can influence epigenetic modification to control selective expression of genes in lymphocytes (Buck et al., 2015; Peng et al., 2016; Tyrakis et al., 2016) . To further elucidate the effects of VHL deficiency on ILC2s, we performed chromatin immunoprecipitation (ChIP) analysis with antibody against histone H3 tri-methylation at the lysine 4 residue (H3K4me3), a transcriptional permissive modification. ILC2s from Vhl fl/fl Zbtb16-cre mice showed decreased modification of H3K4me3 at the Il1rl1 (ST2 gene) loci compared with that from 
CD90.2 + cells as assessed in (F).
Data are represented as mean ± SD; ns, not significant; *p < 0.05, **p < 0.01, and ***p < 0.001 (two-tailed unpaired t test). Data are pooled from or representative of two to three independent experiments or from one experiment with five biological replicates. See also Figure S5 . wild-type mice, whereas ChIP with an isotype-matched control antibody showed negligible signals in the regions tested ( Figures  7D and 7E ). Consistent with Il1rl1 epigenetic changes, we also observed reduced H3K4me3 modification at the Gata3 promoter and Il5 gene loci in VHL-deficient ILC2s, whereas the abundance of H3K4me3 at the Id2 promoter region was comparable (Figure 7F) . These results indicated that VHL deficiency altered epigenetic modification of ST2 gene and the downstream targets in ILC2s.
DISCUSSION
In the present study, we demonstrated that VHL played an important role in promoting the development and effector function of ILC2s through a HIF1a-dependent glycolytic pathway. Although VHL deficiency did not overtly affect the population of immature ILC2s in the bone marrow, the numbers of ILC2s in peripheral non-lymphoid tissues were severely impaired. VHL depletion diminished the airway inflammation induced by papain administration and attenuated the responsiveness of ILC2s to IL-33 treatment. Mechanistically, VHL-deficient ILC2s exhibited enhanced expression of HIF1a and subsequently resulted in enhanced glycolysis. Particularly, the PKM2-pyruvate checkpoint was critically involved in the expression of IL-33 receptor ST2 and subsequent homeostasis of ILC2s through epigenetic modification. Previous studies have used various genetic tools in deleting genes related to the development of ILC lineage cells, such as Il7ra-Cre (Halim et al., 2016; Monticelli et al., 2016; Yu et al., 2015; Zook et al., 2016) , Mx1-Cre (Wong et al., 2012; Yang et al., 2013) , and Vav-Cre (Yagi et al., 2014) . The transcription factor PLZF, which was previously reported to dominate the development and function of NKT cells (Savage et al., 2008) , is transiently expressed in ILC precursors (ILCPs) (Constantinides et al., 2014) . Although PLZF expression marks the ILCP population, it is not essential for the generation of most ILCs, except for ILC2s and liver ILC1s (Constantinides et al., 2014) . Using Zbtb16-cre, we specifically deleted Vhl expression in ILCPs and NKT cells. Loss of VHL in ILCPs had a selective effect on the later development and effector functions of ILC2s, while ILC1 and ILC3 subsets were not obviously affected. The effect of Zbtb16-cre-driven deletion of VHL was intrinsic on ILC2 development in peripheral non-lymphoid tissues as revealed in the mixed bone marrow chimera experiments. These results are consistent with the lineage-tracing study, showing that the majority of ILC2s are traced by PLZF expression in the lineage commitment process, whereas ILC3s are labeled to a much less extent (Constantinides et al., 2014) . However, the current study does not exclude a role of VHL in ILC1s and/or ILC3s, given the preferential effect of Zbtb16-cre on Vhl deletion in ILC2s shown here. As IL-33 is largely produced by epithelium in the peripheral non-lymphoid tissues, the effect of VHL-HIFglycolysis pathway on ST2 expression will provide a reasonable explanation for the observed reduction of mature ILC2s in the lungs and intestine, with only slight effect on bone marrow ILC2s.
HIF1a-mediated glycolysis has emerged as a key regulator for the metabolic checkpoint for the differentiation and activation of immune cells (Buck et al., 2015; Ganeshan and Chawla, 2014) . HIF1a-induced metabolic reprogramming also orchestrates T cell lineage specification. HIF1a-regulated glycolysis serves as a key metabolic checkpoint to cell fate determination between Th17 and Treg cells (Dang et al., 2011; Shi et al., 2011) . VHL-deficient CTLs exhibit enhanced HIF1a expression and glycolysis and produce increased IFN-g, thus promoting the effector response to persistent antigen (Doedens et al., 2013) . Our recent study has demonstrated that loss of VHL in Treg cells causes enhanced glycolysis and disturbs their stability to become IFN-g-secreting inflammatory Treg cells, thus inducing type 1 immune responses and tissue damages . In concordance with these findings, we now demonstrate a detrimental role of VHL-HIF1a-regulated glycolysis in ILC2 maturation and type 2 responses.
Previous reports have established a connection between glucose metabolism and epigenetic regulation in T cells. GAPDH can act as a RNA-binding protein and prevent the translation of cytokine mRNAs containing AU-rich elements in the 3 0 UTR to promote T cell effector function (Chang et al., 2013) . LDHA promotes Th1 cell differentiation by maintaining high amounts of acetyl-CoA to sustain histone acetylation and transcription of interferon-g gene (Peng et al., 2016) . 2-hydroxyglutarate regulates CD8 T cell differentiation through modulation of histone and DNA demethylation (Tyrakis et al., 2016) . We observed that knockdown or inhibition of PKM2 resulted in enhanced ILC2 development, whereas pyruvate treatment or blocking mitochondrial transport of pyruvate and oxidative phosphorylation directly attenuated ILC2 development. Thus, the PKM2-pyruvate checkpoint plays a key role for ILC2 development through ST2 expression. Combining the published data and our observations in this study, we propose a model of equilibrium between glycolysis and oxidative phosphorylation in that the imbalance between the two will alter the epigenetic modification, which involves a collective action of enzymes and metabolites at different checkpoints. In supporting this model, loss of VHL causes the shift from oxidative phosphorylation to glycolysis, which results in altered epigenetic modification of ST2 gene and its downstream targets in ILC2s. Further investigation of the VHL-HIF-glycolysis axis will unveil insights into the detailed molecular nature of the glucose metabolism in ILC2s.
Intestinal ILC2s have been reported to preferentially utilize fatty acid to protect against helminth infection, while blocking glycolysis with 2-DG does not impair ILC2 function (Wilhelm et al., 2016) . In this study, we found that exaggerated glycolysis caused by VHL deletion attenuated ILC2 differentiation. The discrepancy could be that 2-DG blocking could shift the cellular energy production by oxidative phosphorylation using metabolites from other metabolic pathways such as glutamate and fatty acid synthesis, whereas in the VHL-deficient ILC2s, VHL-HIF axis targets selective enzymes and metabolic checkpoints, which could result in different readouts.
Recent studies have recognized that ILC2s are tissue-resident lymphocytes, which can maintain and expand locally under resting physiologic conditions and during acute inflammation (Gasteiger et al., 2015; Moro et al., 2016) . We observed severe decrease of ILC2s in peripheral non-lymphoid tissues of Vhl fl/fl Zbtb16-cre mice at steady state, while the populations of bone marrow ILC2s were comparable, in spite of the abnormal expression of several ILC2-specific markers. It is suggested that bone marrow ILC2s are in the stage of immature ILC2s or their precursors as they lack the maturation marker KLRG1, which is associated with IL-5 and IL-13 production (Hoyler et al., 2012) . A recent study has established a population of IL-25-responsive inflammatory ILC2s (iILC2s) in lung tissue, which have no ST2 expression but have the potential to become natural ILC2s (Huang et al., 2015) . This population is demonstrated as the precursor of ST2-expressing ILC2s during inflammation and infection. Based on our current study, we postulate that ILC2s undergo a two-stage maturation process. At the early stage, they initiate the transcriptional program to acquire general ILC2 properties and stay in quiescence in the bone marrow or maybe other organs. At the late stage, ILC2s respond to the peripheral micro-environmental cues, further express the maturation markers, and are primed to secrete type 2 cytokines rapidly upon allergen stimulation or infection. Our study provides evidence to support the twostage model of ILC2 development, and VHL-HIF1a pathway is critical in the late stage of ILC2 differentiation and functional maturation via the regulation of ST2 expression and IL-33-ST2 pathway. Understanding the molecular mechanisms of how glycolysis governs ILC2 homeostasis may reveal potential targets for therapeutic intervention of ILC2-mediated inflammatory diseases.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
DECLARATION OF INTERESTS
8-10 weeks, the spleen, bone marrow, lungs, and lamina propria of the small and large intestine were collected for analysis. For single bone marrow chimera, Rag2 
Isolation of lymphocytes
For isolation of cells from the thymus, spleen, lymph nodes and liver, tissues were homogenized manually through 70-mm cell strainers. Bone marrow cells were collected by flushing out the marrow from femurs and tibias using a syringe with RPMI-1640 media. Peritoneal cells were collected by flushing the peritoneal cavity with 6 mL of PBS with 2% FBS. BALF cells were collected by gently flushing the lung with two washes of 1 mL of PBS through the trachea. Red blood cells were lysed with ACK buffer (eBioscience). For isolation of cells from the lungs and EWAT, tissues were diced into small pieces and incubated with 1 mg/ml collagenase III (Worthington) and 20 mg/ml DNase I (Roche) in RPMI-1640 media for 45 min at 37 C before being mashed through 70-mm cell strainers. After associated fat tissues and Peyer's patches were removed, intestine was opened longitudinally, cut into 5 mm pieces, and washed with HBSS medium containing 5 mM EDTA and 1 mM DTT for 20 min at 37 C twice to remove epithelial cells. Then, intestinal tissues were digested with 2 mg/ml collagenase type III for 50 min. To isolate leukocytes in the lungs, intestine and liver, digested tissues or cell suspensions were filtered through 70-mm cell strainers and enriched with 40% Percoll gradient after red blood cells were lysed. Single-cell suspensions from all tissues were used for subsequent flow cytometry staining.
Flow cytometry
Samples were pre-incubated with Fc Block (eBioscience) for 10 min. Staining of surface molecules with fluorescently labeled antibodies was performed on ice for 30 min in the dark. For phenotypic analysis by flow cytometry, samples were run on an LSR Fortessa (BD Biosciences) and data were analyzed using FlowJo (Tree Star). For sorting of hematopoietic progenitors or ILC2s from bone marrow cells, lineage negative (Lin À ) cells were first enriched by mouse Lineage Cell Depletion Kit (Miltenyi Biotec) following the manufacturer's instructions. Cells were sorted on an Aria II (BD Biosciences).
Intracellular staining
For measurement of intracellular cytokine expression, cells were isolated ex vivo and stimulated with 50 ng/ml PMA and 500 ng/ml ionomycin, in the presence of GolgiStop (BD Biosciences) for 3 h. Dead cells were excluded by Fixable Viability Dye eFluor 450 (eBioscience). Cells were stained with antibodies to surface antigens, and then fixed and permeabilized with the Cytofix/Cytoperm kit (BD Biosciences), followed by staining with anti-IL-5 (Biolegend) and anti-IL-13 (eBioscience). For analysis of transcription factor expression, cells were stained with antibodies to surface antigens, then fixed and permeabilized with the Foxp3/Transcription Factor Staining Buffer Set (eBioscience) according to the manufacturer's instructions, and stained with anti-GATA3 (eBioscience), anti-RORgt, anti-T-bet (BD Biosciences), or anti-Ki-67 (eBioscience).
For measurement of intracellular HIF1a, Lin À bone marrow cells were cultured in complete media with 10 ng/ml IL-7 (Peprotech) and 10 ng/ml IL-33 (R&D Systems) for 4 days. Cells were collected and stained with antibodies to surface antigens, fixed and permeabilized with the Foxp3/Transcription Factor Staining Buffer Set (eBioscience) according to the manufacturer's instructions, and then stained with anti-HIF1a (R&D Systems). by flow cytometry on BD Aria II. The progenitors were cultured in MEM-a complete media containing 20% FBS, 1% penicillinstreptomycin, 10 ng/ml IL-7 (Peprotech) and 10 ng/ml IL-33 (R&D Systems) on OP9-DL4 stromal cells (from Sunnybrook Research Institute, Canada) treated with mitomycin c. ILC2 differentiation was evaluated by cell surface staining of Lin, CD90.2, Sca1, ST2, CD25, CD44, CD127 and ICOS at 11-20 days after culture. To assess the role of glycolysis related chemicals, inhibitors or metabolites were added on day 9 of culture.
Retroviral transduction
shRNA-containing oligonucleotides (TGCTGTTGACAGTGAGCGACCATAGATGTTACCCTTTATTTAGTGAAGCCACAGATGTAAAT AAAGGGTAACATCTATGGCTGCCTACTGCCTCGGA for scramble, TGCTGTTGACAGTGAGCGCGCTTTGCATCTGATCCCATTCT AGTGAAGCCACAGATGTA GAATGGGATCAGATGCAAAGCG TGCCTACTGCCTCGGA for PKM2) were cloned into the plasmid pLMP-Ametrine. Viral supernatants were prepared from Plat-E packaging cells. CLP-derived cells cultured on OP9-DL4 with IL-7 and IL-33 were infected with viral supernatant in presence of polybrene (5 mg/ml) by centrifugation at 2,500 rpm for 60 min on day 6 of culture. Infected cells were cultured and analyzed on day 16 of culture.
Cytokine profiling BALF, peritoneal lavage fluid, and culture supernatants were collected from mice or cultured cells. The concentrations of IL-5 and/or IL-13 were quantified by using mouse ELISA Kits (eBiosciences) according to the manufacturer's instructions.
RNA isolation and quantitative real-time PCR RNA was extracted from whole cell lysates of isolated lymphocytes with an RNeasy Micro Kit (QIAGEN) and was reversely transcribed to cDNA with a RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific). Quantitative real-time PCR was performed on cDNA with iQ SYBR Green Supermix (Bio-Rad) in triplicates with a CFX96 real-time system (Bio-Rad). Samples were normalized to the expression of gene encoding b-actin. Primer sequences were listed in the Table S1 .
Metabolic assays FACS-sorted ILC2s were cultured with 10 ng/ml IL-7 and IL-33 for 7 days. Cells were plated at 40,000 cells per well and analyzed using an XF96 extracellular analyzer (Seahorse Bioscience). Three consecutive measurements of ECAR (mpH/min) and OCAR (pMoles O2/min) were obtained in XF base media at 37 C under basal conditions, in response to 1 mM oligomycin, 3 mM FCCP, 100 nM rotenone plus 1 mM antimycin A, 5 mM glucose, and 100 mM 2-DG. All chemicals used for these assays were obtained from Sigma-Aldrich. Glycolysis and glycolytic capacity were calculated from average of three measurements following addition of glucose and oligomycin, respectively. Basal OCR and maximal OCR were calculated from average of three measurements before addition of oligomycin and following addition of FCCP, respectively. SRC is calculated as the difference between basal OCR and maximal OCR.
Chromatin immunoprecipitation (ChIP) assay FACS sorted ILC2s were cultured with 10 ng/ml IL-7 and IL-33 for 7 days. For each sample, 40,000 cells were collected and lysed in 19 mL lysis buffer (0.5% NP-40, 0.5% Tween-20, 0.1% SDS and proteinase inhibitor) for 5 min on ice and then subjected to enzymatic digestion by incubating with 19 mL MNase working buffer (100 mM Tris-HCl pH 8.0, 2 mM CaCl2) and 2 mL diluted MNase (0.01 unit/ml; Sigma, N3755) at 37 C for 5 min. The reaction was terminated by adding 5 mL Stop buffer (110 mM Tris-HCl pH 8.0, 55 mM EDTA), and then 45 mL cold 2 3 RIPA buffer (1% Triton X-100, 280 mM NaCl, 0.1% SDS, 0.2% sodium deoxycholate, 5 mM EGTA and proteinase inhibitor). After spinning at max speed at 4 C for 15 min, the supernatant was transferred to a new tube, and 10% was kept as input for later purification. Each chromatin sample was supplemented with 40 mL RIPA buffer (10 mM Tris-HCl pH 8.0, 140 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.1% DOC, 1 mM EDTA) and then incubated with 1 mg H3K4me3 (Abcam, ab8580) or rabbit isotype control IgG (Abcam, ab171870) overnight with rotation at 4 C. The next day, the sample was incubated with 100 mg protein A/G dynabeads (Life Technologies) for another 2 h. The beads were washed five times with 150 mL RIPA buffer and once with 150 mL LiCl buffer (250 mM LiCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.5% NP-40, 0.5% DOC). After washing, the beads were resuspended with 95 ul TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA) supplemented with 5 mL proteinase K (10 mg/ml; Roche) and incubated at 55 C with shaking for 90 min to digest proteins. The supernatant was collected and DNA was purified by phenol-chloroform extraction and ethanol precipitation. Enrichment of histone modifications were analyzed by qPCR using validated primers described in Table S1 . The ratio of precipitated DNA to input DNA was calculated for comparison of histone modification levels between different samples.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical significance was assessed by unpaired two-tailed t test with Graphpad Prism 6. P values of < 0.05 were considered statistically significant. ''n'' numbers indicate number of mice for in vivo studies or biological replicates for in vitro experiments.
